Akebia Therapeutics, Inc. (AKBA) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
8.85
-9% vs avg
5yr avg: 9.75
30Y Low9.8·High9.8
P/FCF
5.78
-5% vs avg
5yr avg: 6.09
30Y Low6.1·High7.1
P/B Ratio
↑
11.67
-8% vs avg
5yr avg: 12.64
30Y Low1.0·High20.2
ROE
↑
-16.4%
↓+89% vs avg
5yr avg: -143.2%
30Y Low-238%·High-16%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AKBA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Akebia Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 5.8x P/FCF, 5% below the 5-year average of 6.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $393M | $414M | $401M | $232M | $105M | $375M | $388M | $748M | $646M | $647M | $393M |
| Enterprise Value | $208M | $229M | $538M | $294M | $115M | $361M | $285M | $709M | $557M | $577M | $205M |
| P/E Ratio → | -74.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.66 | 1.75 | 2.50 | 1.19 | 0.36 | 1.77 | 1.32 | 2.23 | 3.11 | 3.63 | 255.79 |
| P/B Ratio | 11.67 | 12.70 | — | — | 20.17 | 5.07 | 1.57 | 1.90 | 1.02 | 5.42 | 5.76 |
| P/FCF | 5.78 | 6.09 | — | — | — | — | — | — | — | — | 7.11 |
| P/OCF | 5.78 | 6.09 | — | — | — | — | — | — | — | — | 6.78 |
P/E links to full P/E history page with 30-year chart
AKBA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Akebia Therapeutics, Inc.'s enterprise value stands at 8.9x EBITDA, 9% below its 5-year average of 9.8x. The Healthcare sector median is 14.1x, placing the stock at a 37% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.97 | 3.36 | 1.51 | 0.39 | 1.71 | 0.97 | 2.12 | 2.68 | 3.24 | 133.74 |
| EV / EBITDA | 8.85 | 9.75 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 8.85 | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 3.37 | — | — | — | — | — | — | — | — | 3.72 |
AKBA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Akebia Therapeutics, Inc. earns an operating margin of 9.9%. Operating margins have expanded from -23.8% to 9.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -16.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.3% | 83.3% | 60.6% | 61.9% | 92.3% | 61.5% | 78.3% | 56.6% | 96.3% | 99.7% | -7443.0% |
| Operating Margin | 9.9% | 9.9% | -31.5% | -23.8% | -27.6% | -125.0% | -128.2% | -85.5% | -85.8% | -44.9% | -8889.9% |
| Net Profit Margin | -2.3% | -2.3% | -43.3% | -26.7% | -32.2% | -133.3% | -130.6% | -83.5% | -82.7% | -43.2% | -8843.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.4% | -16.4% | — | — | -237.8% | -175.4% | -119.8% | -54.3% | -45.5% | -82.1% | -136.3% |
| ROA | -1.8% | -1.8% | -30.0% | -17.4% | -21.3% | -48.1% | -54.4% | -31.6% | -25.3% | -23.2% | -61.3% |
| ROIC | — | — | -64.0% | -153.4% | -162.0% | -193.5% | -113.3% | -47.6% | -44.9% | -121.9% | — |
| ROCE | 13.3% | 13.3% | -35.8% | -25.1% | -32.7% | -72.9% | -74.1% | -44.3% | -37.5% | -39.4% | -86.1% |
AKBA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $185M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 19.08 | 1.84 | 0.51 | 0.27 | 0.02 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -5.67 | — | — | 1.78 | -0.19 | -0.42 | -0.10 | -0.14 | -0.59 | -2.75 |
| Net Debt / EBITDA | -7.87 | -7.87 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | -2.72 | — | — | — | — | — | — | — | — | -3.39 |
| Interest Coverage | — | — | -2.78 | -7.67 | -5.15 | -13.27 | -42.59 | -204.49 | — | — | — |
Net cash position: cash ($185M) exceeds total debt ($0)
AKBA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.13x means Akebia Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | 1.13 | 1.41 | 1.18 | 1.43 | 1.04 | 1.98 | 1.49 | 1.76 | 2.48 | 2.59 |
| Quick Ratio | 1.04 | 1.04 | 1.21 | 1.03 | 1.26 | 0.90 | 1.66 | 0.93 | 1.33 | 2.48 | 2.59 |
| Cash Ratio | 1.13 | 1.13 | 0.64 | 0.43 | 0.70 | 0.57 | 1.44 | 0.71 | 1.21 | 2.20 | 2.28 |
| Asset Turnover | — | 0.63 | 0.73 | 0.81 | 0.82 | 0.40 | 0.46 | 0.43 | 0.21 | 0.49 | 0.01 |
| Inventory Turnover | 2.53 | 2.53 | 3.89 | 4.73 | 1.04 | 2.22 | 1.05 | 1.25 | 0.07 | — | — |
| Days Sales Outstanding | — | 72.68 | 78.31 | 73.69 | 50.27 | 88.95 | 35.40 | 42.34 | 29.28 | 70.17 | 8042.60 |
AKBA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Akebia Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 17.3% | 16.4% | — | — | — | — | — | — | — | — | 14.1% |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $257M | $211M | $187M | $183M | $166M | $138M | $118M | $117M | $44M | $38M |
Peer Comparison
Compare AKBA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AKBAYou | $393M | -74.0 | 8.9 | 5.8 | 83.3% | 9.9% | -16.4% | — | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 PTGX | $7B | -50.7 | — | 118.3 | 97.3% | -343.6% | -20.2% | -21.8% | — |
 CYCN | $14M | -3.0 | — | — | 100.0% | -239.8% | -39.3% | -65.1% | — |
 ANIP | $2B | 25.3 | 9.0 | 9.6 | — | 12.6% | 16.2% | 11.2% | 1.6 |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 PRTA | $602M | -2.5 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 FXNC | $249M | 14.0 | 5.9 | 11.8 | 74.0% | 19.6% | 10.0% | 7.7% | 1.9 |
 GSK | $102B | 6.7 | 8.4 | 12.8 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 AMGN | $179B | 23.3 | 14.1 | 22.1 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 RPRX | $22B | 28.2 | 19.2 | 8.7 | 100.0% | 65.6% | 7.7% | 6.7% | 5.7 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See AKBA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AKBA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AKBA vs FOLD
Side-by-side business, growth, and profitability comparison vs Amicus Therapeutics, Inc..
Start ComparisonAKBA — Frequently Asked Questions
Quick answers to the most common questions about buying AKBA stock.
What is Akebia Therapeutics, Inc.'s P/E ratio?
Akebia Therapeutics, Inc.'s current P/E ratio is -74.0x. This places it at the 50th percentile of its historical range.
What is Akebia Therapeutics, Inc.'s EV/EBITDA?
Akebia Therapeutics, Inc.'s current EV/EBITDA is 8.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 9.8x.
What is Akebia Therapeutics, Inc.'s ROE?
Akebia Therapeutics, Inc.'s return on equity (ROE) is -16.4%. The historical average is -97.1%.
Is AKBA stock overvalued?
Based on historical data, Akebia Therapeutics, Inc. is trading at a P/E of -74.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Akebia Therapeutics, Inc.'s profit margins?
Akebia Therapeutics, Inc. has 83.3% gross margin and 9.9% operating margin.